Search results for "Angiogenesis Inhibitors"

showing 10 items of 100 documents

An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy.

2019

Introduction: The angiogenesis mechanism is considered a crucial point in neoplastic development. A growing number of multi-targeted tyrosine kinase inhibitors (TKI) has been developed and approved for cancer treatment during the last few years. Cardiac side effects still remain an issue to manage nowadays. These drugs mechanisms and toxicities have already been discussed, hence the authors will report updates on these already available drugs. Area covered: This manuscript provides an updated review on the new mechanisms involved in angiogenesis and cardiotoxicity that are TKI-related. Here is reported an overview of the already available and the most recent TKIs under investigation in the …

OncologyTumor angiogenesismedicine.medical_specialtyAngiogenesisupdateVEGFR-TKIAngiogenesis InhibitorsAntineoplastic Agents030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsmedicineAnimalsHumansPharmacology (medical)Cardio oncologyCooperative BehaviorCrucial pointProtein Kinase InhibitorsNeovascularization Pathologicbusiness.industrycardiovasculartoxicityGeneral MedicineCardiotoxicityrespiratory tract diseasesReceptors Vascular Endothelial Growth Factor030220 oncology & carcinogenesisoncologybusinessTyrosine kinasemanagementExpert opinion on drug safety
researchProduct

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

2011

Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease. Outcome measures included progression-free survival, first analyzed per protocol and then updated, and interim overall survi…

Oncologymedicine.medical_specialtyBevacizumabCyclophosphamidePaclitaxelMedizinAngiogenesis InhibitorsCarcinoma Ovarian EpithelialAntibodies Monoclonal HumanizedDisease-Free SurvivalCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCarcinomaMedicineHumansNeoplasms Glandular and EpithelialSurvival analysis030304 developmental biologyGynecologyOvarian Neoplasms0303 health sciencesbusiness.industryArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapySurvival AnalysisCarboplatin3. Good healthBevacizumabRegimenchemistry030220 oncology & carcinogenesisQuality of LifeFemalebusinessOvarian cancermedicine.drug
researchProduct

Maxillary osteonecrosis associated to antiangiogenic drugs.

2009

Oncologymedicine.medical_specialtyBevacizumabbusiness.industryMEDLINEOsteonecrosisAntibodies MonoclonalAngiogenesis Inhibitors:CIENCIAS MÉDICAS [UNESCO]Antibodies Monoclonal HumanizedMaxillary DiseasesBevacizumabText miningOtorhinolaryngologyInternal medicineUNESCO::CIENCIAS MÉDICASMonoclonalMedicineHumansSurgerybusinessGeneral Dentistrymedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and aflibercept

2022

Abstract Introduction To evaluate the effects of combined therapy using intravitreal Aflibercept (IVA) and photodynamic therapy (PDT) on polypoidal choroidal vasculopathy related to pachychoroid disease (PPCV).Methods Patients with PPCV were treated with PDT combined with 3 IVA injections on a monthly basis, followed by pro re nata criteria. The 12-month follow-up consisted of multiple revaluations of visual acuity and SSOCT parameters of clinical activity.Results Nineteen eyes were included in the study; mean age was 65.5 years. Visual acuity improved after 12 months (0.35 ± 0.25 to 0.2 ± 0.20 logMAR, p = 0.005). Percentage of eyes with intraretinal and subretinal fluid reduced from baseli…

Oncologymedicine.medical_specialtygenetic structuresRecombinant Fusion Proteinsmedicine.medical_treatmentAngiogenesis InhibitorsPhotodynamic therapyPhotodynamic therapyCombined treatmentInternal medicinePolypoidal choroidal vasculopathyHumansMedicinePachychoroidFluorescein AngiographyAgedRetrospective StudiesAfliberceptbusiness.industryeye diseasesOphthalmologyReceptors Vascular Endothelial Growth FactorTreatment OutcomePhotochemotherapyIntravitreal InjectionsbusinessAfliberceptSwept Source OCTTomography Optical Coherencemedicine.drugInternational Ophthalmology
researchProduct

Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.

2008

Evaluate the efficacy of intravitreal pegaptanib sodium (Macugen®) in refractory pseudophakic cystoid macular oedema (CME). Prospective, nonrandomized, interventional case series. Four eyes of four patients with refractory pseudophakic CME to pars plana vitrectomy and intravitreal bevacizumab and triamcinolone, were treated with pegaptanib sodium, with a mean follow up of 4 months. Pre- and postinfection examinations included assessment of best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study chart (ETDRS), fluorescein angiography (FA), and optical coherence tomography (OCT). Visual acuity increased in all patients after intravitreal pegaptanib sodium. OCT…

Pars planaMalemedicine.medical_specialtyVisual acuityTriamcinolone acetonidegenetic structuresPseudophakiamedicine.medical_treatmentPegaptanibIntraocular lensVitrectomyAngiogenesis InhibitorsMacular EdemaVitrectomymedicinePegaptanib SodiumHumansProspective StudiesFluorescein AngiographyAgedDiabetic Retinopathymedicine.diagnostic_testbusiness.industryAptamers NucleotideMiddle AgedFluorescein angiographyeye diseasesSurgeryOphthalmologymedicine.anatomical_structureTreatment OutcomeFemalesense organsmedicine.symptombusinessTomography Optical Coherencemedicine.drugEye (London, England)
researchProduct

Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers

2012

Objective To investigate the effect of antiangiogenic treatment on experimental endometriotic lesion nerve fibers. Design Heterologous mouse model of endometriosis. Setting University Institute IVI, University Hospital La Fe. Animal(s) Ovariectomized nude mice (n = 16) receiving human endometrial fragments from oocyte donors (n = 4). Intervention(s) Endometrium fragments stuck in the peritoneum of 5-week-old female nude mice treated with vehicle (n = 8) and antiangiogenic agent cabergoline (n = 8; Cb 2, 0.05 mg/kg/day) for 14 days. Main Outcome Measure(s) Immunofluorescence analysis of von-Willebrand factor (vWF) and vascular smooth muscle cells (αSMA) for evaluating the number of immature …

Pathologymedicine.medical_specialtyCabergolineTime FactorsAngiogenesisOvariectomyEndometriosisEndometriosisFluorescent Antibody TechniqueMice NudeAngiogenesis InhibitorsNerve fiberPeritoneal DiseasesEndometriumEndometriumMicechemistry.chemical_compoundNerve FibersPeritoneumvon Willebrand FactorAnimalsHumansMedicineMast CellsErgolinesNeovascularization Pathologicbusiness.industryMacrophagesObstetrics and GynecologyMast cellmedicine.diseaseImmunohistochemistryActinsVascular endothelial growth factorDisease Models Animalmedicine.anatomical_structureReproductive MedicinechemistryMicrovesselsImmunologyFemalebusinessBiomarkersBlood vesselFertility and Sterility
researchProduct

Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometri…

2015

Objective To assess the therapeutic potential of polyinosine-polycytidylic acid, a double-stranded RNA molecule with selective proapoptotic and antiangiogenic activity, complexed with polyethyleneimine (pIC PEI ) in treating endometriosis. Design A heterologous mouse model of endometriosis was created by injecting human endometrial fragments into the peritoneum. Endometrial fragments were engineered to express the fluorescent protein mCherry as a reporter to monitor status over the course of the 4-week study. Setting University-affiliated infertility center. Animal(s) Ovariectomized and hormone-replaced nude mice (n = 30) injected with fluorescent-labeled human endometrial fragments at 4–6 …

Pathologymedicine.medical_specialtyTime FactorsOvariectomyEndometriosisEndometriosisHeterologousMice NudeAngiogenesis InhibitorsApoptosisEndothelial Growth FactorsBiologyEndometriumPeptides CyclicNeovascularizationEndometriumPeritoneumGenes ReportermedicineAnimalsHumansPolyethyleneimineCell ProliferationNeovascularization PathologicCell growthEstrogen Replacement TherapyObstetrics and Gynecologymedicine.diseaseMolecular biologyDisease Models AnimalLuminescent Proteinsmedicine.anatomical_structurePoly I-CReproductive MedicineApoptosisHeterograftsFemalemedicine.symptommCherryFertility and sterility
researchProduct

Anti-angiogenic therapies in prostate cancer.

2012

Prostate cancer (PCa) is the second most common type of cancer among men in Western societies. Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.

PharmacologyOncologyMalePathologymedicine.medical_specialtyEvidence-Based Medicinebusiness.industryAngiogenesisClinical BiochemistryAnti angiogenicCancerProstatic NeoplasmsAngiogenesis InhibitorsEvidence-based medicineurologic and male genital diseasesmedicine.diseaseClinical trialProstate cancerClinical evidenceInternal medicineDrug DiscoverymedicineHumansbusinessExpert opinion on biological therapy
researchProduct

Cytotoxicity of some Cameroonian spices and selected medicinal plant extracts

2011

Abstract Ethnopharmacological relevance Several medicinal plants and spices are used traditionally to treat cancers in Cameroon. Aim Methanol extracts from thirty-four spices and plants, with related ethnobotanical use were investigated for their in vitro cytotoxicity on the human pancreatic cancer cell line MiaPaCa-2, leukemia CCRF-CEM cells and their multidrug resistant (MDR) subline CEM/ADR5000, and the normal human umbilical vein endothelial cells (HUVECs). In addition the anti-angiogenic properties of the most active extracts were investigated. Material and methods The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay was used for cyto…

PharmacologyXylopia aethiopicaEchinopsPlants MedicinalbiologyTraditional medicinePlant ExtractsAngiogenesis Inhibitorsbiology.organism_classificationAntineoplastic Agents PhytogenicPancreatic NeoplasmsMultiple drug resistanceDorsteniaCell Line TumorDrug DiscoveryCancer cellOfficinalisHumansCameroonDrug Screening Assays AntitumorSpicesCytotoxicityMedicinal plantsCells CulturedJournal of Ethnopharmacology
researchProduct

Nintedanib in non-small cell lung cancer: from preclinical to approval

2015

Angiogenesis is a driving force of a tumor’s development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and many others. The latest drug of this class to be approved for patients with non-small cell lung cancer (NSCLC) was nintedanib, a triple angiokinase inhibitor. This molecule targets vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) pathways, avoiding the tumor’s switch to normal escape mechanisms. The pharmacokine…

Pulmonary and Respiratory MedicineSorafenibIndolesLung NeoplasmsBevacizumabBIBF1120Settore MED/06 - Oncologia Medicamedicine.drug_classDrug Evaluation PreclinicalAngiogenesis InhibitorsAntineoplastic AgentsAdenocarcinomaPharmacologyNSCLCVandetanibTyrosine-kinase inhibitorRamucirumabchemistry.chemical_compoundtyrosine kinase inhibitorCarcinoma Non-Small-Cell LungnintedanibmedicineMotesanibAnimalsHumansPharmacology (medical)Drug Approvalnon-small cell lung cancerlcsh:RC705-779Neovascularization PathologicSunitinibbusiness.industrylcsh:Diseases of the respiratory systemchemistryCancer researchNintedanibHuman medicinebusinessantiangiogenic drugmedicine.drugTherapeutic Advances in Respiratory Disease
researchProduct